Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of oral BEZ235 monotherapy in malignant PEComa
2011-001884-39Phase 2Terminated
- Sponsor
- Novartis
- Start
- Sep 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dactolisib in Perivascular epithelioid cell neoplasm (PEComa), Bone and soft tissue sarcoma and cancer, sponsored by Novartis. Primary endpoint: Objective Response Rate. Started Sep 2012; status: terminated.
02
Drugs
dactolisib
03
Conditions
Perivascular epithelioid cell neoplasm (PEComa)Bone and soft tissue sarcomacancer
Beyond the preview
Go deeper on 2011-001884-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001884-39.